Ravulizumab 300mg/3ml solution for infusion vials
NHS hospitals in England used £18,521,838 of indicative cost of Ravulizumab 300mg/3ml solution for infusion vials in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 11.5% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Ravulizumab 300mg/3ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Ravulizumab 300mg/3ml solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Leeds Teaching Hpls Nhs Trust | £4,183,959 |
| King's College Hpl Nhs Foundation Trust | £4,002,639 |
| Nottingham University Hospitals Trust | £1,604,682 |
| University Hospital Southampton Nhs Ft | £1,223,910 |
| Manchester University Nhs Ft | £1,051,656 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £738,879 |
| University Hpls North Midlands Nhs Trust | £725,280 |
| Aintree University Hospital Nhs Ft | £661,818 |
| Univ Hpls Bristol Nhs Foundation Trust | £611,955 |
| Oxford University Hospitals Nhs Ft | £543,960 |
The primary-care picture
Ravulizumab is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Ravulizumab medicine page.